{"filing":{"accession_number":"0001193125-26-346888","cik":"0001593899","ticker":"AVIR","company_name":"Atea Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"d165663d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1593899/000119312526346888/d165663d8k.htm"},"events":[{"id":27224,"run_id":24799,"accession_number":"0001193125-26-346888","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing Atea's financial results for Q2 2026 (three and six months ended June 30, 2026), including operating expenses, net loss, cash position, and per-share metrics. The press release, furnished as Exhibit 99.1, announces \"financial results for the second quarter ended June 30, 2026\" alongside a business update on clinical trial progress. The financial tables show condensed consolidated statements of operations and balance sheet data, which are hallmarks of an earnings disclosure under Item 2.02.","company_name":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28660,"accession_number":"0001193125-26-346888","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Atea's financial results for Q2 2026 (three and six months ended June 30, 2026), including operating expenses, net loss, cash position, and per-share metrics. The press release, furnished as Exhibit 99.1, announces \"financial results for the second quarter ended June 30, 2026\" alongside a business update on clinical trial progress. The financial tables show condensed consolidated statements of operations and balance sheet data, which are hallmarks of an earnings disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:20:51.485737+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28660,"accession_number":"0001193125-26-346888","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Atea's financial results for Q2 2026 (three and six months ended June 30, 2026), including operating expenses, net loss, cash position, and per-share metrics. The press release, furnished as Exhibit 99.1, announces \"financial results for the second quarter ended June 30, 2026\" alongside a business update on clinical trial progress. The financial tables show condensed consolidated statements of operations and balance sheet data, which are hallmarks of an earnings disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:20:51.485737+00:00","company_name":"Atea Pharmaceuticals, Inc.","ticker":"AVIR","filing_date":"2026-08-12"}]}